Welcome to our dedicated page for Axcelis Tech Ord news (Ticker: ACLS), a resource for investors and traders seeking the latest updates and insights on Axcelis Tech Ord stock.
Axcelis Technologies reports developments tied to its role as a supplier of ion implantation systems and process applications for semiconductor manufacturing. Company updates commonly cover quarterly results, demand trends across memory, power, compound semiconductor and mature-node markets, and the performance of its customer support and installed-base services business.
News also includes technical participation at semiconductor industry conferences, lifecycle support for Purion-based implant platforms, sustainability targets for greenhouse gas emissions, investor-conference activity and governance changes such as finance leadership transitions. The recurring business context centers on equipment used in integrated-circuit fabrication and aftermarket services including spare parts, upgrades, maintenance and training.
Axcelis Technologies (Nasdaq: ACLS) will release its third quarter 2022 financial results on November 2, 2022, at 4:00 p.m. ET. A follow-up conference call to discuss the results is scheduled for November 3, 2022, at 8:30 a.m. ET. Interested parties can access the call via an audio webcast on the company's website. The company specializes in high-productivity solutions for the semiconductor industry, particularly in the area of ion implantation systems.
Axcelis Technologies, Inc. (NASDAQ: ACLS) announced the qualification of its Purion XEmax high energy ion implant system for production at a leading CMOS image sensor manufacturer. This advancement is expected to enhance image sensor technology and production capabilities, driving growth in the image sensor market. The Purion XEmax is designed for high-performance applications, featuring advanced filtration systems to maintain photodiode quality. This move reflects Axcelis’ commitment to innovation in semiconductor solutions amid increasing demand.
Axcelis Technologies (NASDAQ: ACLS) announced its sponsorship and participation in the International Conference on Ion Implantation Technology 2022, set for September 25-29 in San Diego, CA. This marks over 40 years of Axcelis's involvement in the conference series. The event will focus on advances in ion implantation technologies, featuring presentations on topics such as the Purion H200™ single wafer implanter and advanced angle control solutions. Axcelis aims to address critical challenges in the semiconductor industry through these discussions.
Axcelis Technologies, based in Beverly, Mass, announced its participation in two upcoming investor conferences. The D.A. Davidson Big Sky Technology Summit will occur on August 22-23, 2022, with one-on-one meetings scheduled for August 23rd. Additionally, Axcelis will attend the Needham Virtual 3rd Annual SemiCap and EDA Conference on August 25, 2022, facilitating one-on-one meetings for interested investors. Axcelis has over 40 years of experience in the semiconductor industry, specializing in ion implantation solutions.
Axcelis Technologies (ACLS) reported robust financial results for Q2 2022, achieving $221.2 million in revenue, a rise from $203.6 million in Q1. The operating profit increased to $54.1 million, with net income at $44.2 million or $1.32 per diluted share. Gross margin improved to 44.8%. The company experienced record system bookings of $432.8 million and backlog reaching $869.5 million. For FY 2022, revenue is projected to exceed $875 million, with a gross margin of approximately 42.5%.
Axcelis Technologies (Nasdaq: ACLS) has officially opened its new Axcelis Asia Operations Center in Pyeongtaek-Si, Korea, significantly increasing its manufacturing capacity. The state-of-the-art facility spans over 44,000 square feet and is certified by ISO 45001 for occupational health and safety. Initial shipments commenced in Q1, and the center aims to enhance customer relationships and streamline operations across Asia. This investment is expected to create numerous local jobs in various functions.
Axcelis Technologies (Nasdaq: ACLS) announced robust financial expectations for Q2 2022, projecting revenues exceeding $215 million, a gross margin of approximately 41%, operating profit around $41 million, and earnings per diluted share of about $1.00. The company cites strong demand for ion implantation solutions within the semiconductor sector, with booking levels supporting over $850 million in total revenue for the year. A conference call is scheduled for August 4, 2022, to discuss these results in further detail.
Axcelis Technologies (Nasdaq: ACLS) has announced significant progress in the power device segment with multiple shipments of its Purion H200 Si 200mm and SiC Power Series™ 150mm high current implanters to major power device chipmakers in Asia. These systems are intended for high-volume production in the automotive sector, which is experiencing rapid growth.
Executive Vice President Bill Bintz stated that the power device segment is projected to comprise 30% to 40% of their system sales in 2022, highlighting the company's commitment to support electric vehicle technology through advanced manufacturing solutions.
Axcelis Technologies (NASDAQ: ACLS) is set to participate in the 14th Annual CEO Summit on July 13, 2022, taking place at the St. Regis Hotel in San Francisco, CA. This event allows accredited investors and research analysts to engage with the management teams of various participating companies. Axcelis, a leader in ion implantation solutions for the semiconductor industry, will make presentation materials available on its investor page. Early RSVP is advised as space is limited, with the registration deadline on July 1, 2022.
Axcelis Technologies (Nasdaq: ACLS) reported multiple shipments of Purion M™ medium current implanters, enhancing its presence in the semiconductor industry. These include follow-on orders and three new placements across the US, Europe, and Asia, shipped in Q2 2022. Executive VP Bill Bintz noted that the mature process technology market continues to be robust, indicating potential revenue growth from these new tool placements. This strategic move aims to expand the company's customer base and revenues in a vital segment of the industry.